These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 10388304)

  • 1. [Modified cost-benefit analysis takes equity into consideration. Treatment of brain tumors is more cost-effective than hip replacement].
    Lindholm L; Henriksson R; Rosén M; Bergenheim T; Salander P
    Lakartidningen; 1999 Jun; 96(22):2749-54. PubMed ID: 10388304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
    Krummenauer F; Günther KP; Witzlebf WC
    Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of primary total hip replacement.
    O'Shea K; Bale E; Murray P
    Ir Med J; 2002 Jun; 95(6):177-80. PubMed ID: 12171266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs.
    Räsänen P; Paavolainen P; Sintonen H; Koivisto AM; Blom M; Ryynänen OP; Roine RP
    Acta Orthop; 2007 Feb; 78(1):108-15. PubMed ID: 17453401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total joint replacement: a cost-effective procedure for the 1990s.
    Hirsch HS
    Med Health R I; 1998 May; 81(5):162-4. PubMed ID: 9617092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of core decompression.
    Soohoo NF; Vyas S; Manunga J; Sharifi H; Kominski G; Lieberman JR
    J Arthroplasty; 2006 Aug; 21(5):670-81. PubMed ID: 16877152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Priority setting in practice: what is the best way to compare costs and benefits?
    Wilson EC; Peacock SJ; Ruta D
    Health Econ; 2009 Apr; 18(4):467-78. PubMed ID: 18561215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global cost-effectiveness of cataract surgery.
    Lansingh VC; Carter MJ; Martens M
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analyses of elective orthopaedic surgical procedures in patients with inflammatory arthropathies.
    Osnes-Ringen H; Kvamme MK; Kristiansen IS; Thingstad M; Henriksen JE; Kvien TK; Dagfinrud H
    Scand J Rheumatol; 2011 Mar; 40(2):108-15. PubMed ID: 21241197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
    Borg S; Glenngård AH; Osterborg A; Persson U
    Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
    Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
    Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Oregon formula: a better method of allocating health care resources.
    Ostbye T; Speechley M
    Nord Med; 1992; 107(3):92-5. PubMed ID: 1549459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.